Based on 1 active firms as of Nov 18, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$30.00
+1746.2% upside
Average target across 1 active firms as of Nov 18, 2026 vs $1.63 current
Highest Target$30.00
Average Target$30.00
Lowest Target$30.00
ERNA analyst recommendation trends
86420
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Strong BuyBuyNeutralSellStrong Sell
RATING
JUN
JUL
AUG
SEP
OCT
NOV
Strong Buy
0
0
0
0
0
0
Buy
1
1
1
1
1
1
Neutral
0
0
0
0
0
0
Sell
0
0
0
0
0
0
Strong Sell
0
0
0
0
0
0
Total
1
1
1
1
1
1
As of Nov 18, 2026, 1 of 1 active firms rate ERNA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ERNA EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 1 analysts
Next period, 1 analysts expect Ernexa Therapeutics Inc. to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-18.02, growing to $-1.86 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Ernexa Therapeutics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ERNA.
#1
KR
Kumaraguru Raja
Brookline Capital Markets
Buy
$30.00+1746.2% to target
Coverage
—
+ Follow
ERNA stock forecast FAQ
What is ERNA's average 12-month price target?+
The 1 active firms with a live target average $30.00 for Ernexa Therapeutics Inc. over the next 12 months, ranging from a $30.00 high to a $30.00 low, as of Nov 18, 2026.
Is ERNA stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 18, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ERNA?+
1 active firms have a recognized rating on Ernexa Therapeutics Inc. as of Nov 18, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ERNA?+
Among analysts who currently cover ERNA, Kumaraguru Raja of Brookline Capital Markets has the strongest overall Quantellect track record. Their current call is Buy with a $30.00 target.
What is Ernexa Therapeutics Inc.'s projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 1 analysts. Full-year EPS is projected at $-18.02, rising to $-1.86 the following year.
How much revenue is Ernexa Therapeutics Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ERNA lately?+
As of Nov 18, 2026, 1 of 1 active firms rate ERNA a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ERNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.